4D Molecular Therapeutics Investor Day 2026 - 4D MOLECULAR THERAPEUTICS INC

Financial Performance:

• The company did not report specific quarterly revenue or GAAP financial metrics as this was an Investor Day focused on product positioning; however, they highlighted a strong cash runway extending into the second half of 2028.
• Management noted the current wet AMD market is valued at approximately $16 billion globally, with 60% in the US, driven by an aging population and incidence growth.
• Real-world data indicates a "value erosion" in the current "buy and bill" model, where patient attrition reduces the capture of potential reimbursement value from 100% (theoretical) to roughly 53% in practice due to missed visits and discontinuation.
• 4150 is positioned to reverse this value erosion by capturing upfront reimbursement for a multi-year therapy (10 visits vs. 300 injections for 10 patients over 5 years) while eliminating the financial loss associated with non-adherence.

Guidance and Future Outlook:

• Pivotal Phase 3 readouts are scheduled for Q2 2027 (Forefront 1, North America, treatment-naive) and the second half of 2027 (Forefront 2, Global, mixed population).
• The commercial launch is anticipated following 2027 approvals, with a strategy to shift the treatment paradigm from episodic bolus therapy to a "backbone" lifelong therapy.
• Early adoption is expected in Year 1 among high-need patients (25% of the market), expanding to moderate and low-need patients in Years 2–4 as reimbursement confidence (J-code acquisition) and real-world safety data solidify.
• Management anticipates a significant portion of the market (potentially 20-40% of newly diagnosed patients) could be considered for 4150 as the therapy matures.

Business Segments and Product Lines:

• Core Product (4150): A gene therapy vector (R100) delivering Aflibercept and RNAi against VEGF-C, designed for a single in-office intravitreal injection to provide continuous, lifelong expression of anti-VEGF.
• Target Product Profile: Aims to be a "backbone" therapy for all wet AMD patients, offering potential for lifelong injection-free periods, vision preservation, and significantly reduced treatment burden.
• Clinical Data: Phase 2b results demonstrated 46% of eyes requiring no additional injections for two years (78% burden reduction) and 87% reduction in burden for recently diagnosed patients; safety profile showed only mild, transient inflammation (resolved with topical steroids) over four years.
• Operational Model: Designed to fit seamlessly into the existing "buy and bill" Medicare Part B reimbursement structure without requiring surgical implants or specialized handling.

Market and Competitive Landscape:

• Market Dynamics: The market is growing 5% annually; despite the introduction of longer-acting agents (e.g., Vabizim), average treatment intervals have only increased modestly (from 55 to 67 days) over the last five years, leaving a massive unmet need for continuous control.
• Competitive Advantage: Unlike current bolus therapies (finite durability) and the Port Delivery System (surgical, refill-dependent), 4150 offers continuous disease control via a non-surgical, one-time injection.
• Stakeholder Alignment: Survey data indicates 85% of retina specialists and 71% of payers view gene therapy as the mechanism with the most potential to address unmet needs in AMD.
• Patient Demand: 90% of patients surveyed expressed interest in asking their physicians about 4150 due to the desire to avoid blindness and reduce the anxiety of frequent visits.

Risks and Challenges:

• Safety Concerns: Primary risks include intraocular inflammation (managed with a 20-week steroid taper) and potential steroid-induced cataracts or elevated intraocular pressure; however, management consensus is that these are manageable and preferable to vision loss from episodic treatment gaps.
• Adoption Friction: Initial adoption may be limited by the need to secure a permanent J-code for reimbursement and demonstrate safety in the real world, potentially taking 6–12 months post-approval for broader uptake.
• Patient Compliance: Risk of patients dropping off therapy due to logistical hurdles (transportation, caregiving) is mitigated by 4150's single-dose model, but real-world adherence to the initial steroid taper remains a clinical consideration.
• Regulatory Path: While RMAT, PRIME, and PMDA interactions are positive, final approval relies on non-inferiority results at Week 52 in Phase 3 trials.

Management Commentary and Tone:

• Tone was highly confident, optimistic, and patient-centric, emphasizing a "paradigm shift" from episodic care to continuous disease control.
• CEO David Kern and executives repeatedly stated that the current treatment model is "not good enough" because it fails to protect vision long-term due to missed doses.
• Management expressed strong conviction that the combination of clinical data, Phase 3 design, and stakeholder enthusiasm positions the company for broad commercial success starting in 2027.
• KOLs (Key Opinion Leaders) reinforced confidence, noting that the safety profile (episodic vs. chronic inflammation) and logistical simplicity of 4150 address the primary barriers of previous gene therapies.

Analyst Questions and Answers:

• BCVA Outcomes: Expectation for non-inferiority analysis shows a 6–8 letter gain for treatment-naive patients; analysis will compare against baseline (first injection) to match historical trial standards (e.g., Tenaya/Lucentis).
• Screening & Response Criteria: Response criteria (15% response, complete fluid resolution) are designed to exclude "non-responders" early to protect vision outcomes but are not expected to screen out a large volume of patients; focus is on maximizing efficacy while safeguarding the primary endpoint.
• Redosing/Bilateral Dosing: The companion bilateral study is underway; commercial launch will support bilateral treatment, likely timed 1–3 months after the first eye treatment (post-steroid taper) based on physician discretion and patient demand.
• Steroid Management: Physicians noted that a 20-week steroid taper is manageable, with cataracts viewed as an inevitable and replaceable risk compared to the non-replaceable risk of vision loss.
• Adoption Timeline: Initial use expected in Year 1 for high-need patients and Medicare beneficiaries (no auth); broad expansion to moderate/low-need patients projected for Years 2–4 following J-code acquisition and payer familiarity.

Other Key Points:

• 4150 Target: Designed to treat 4 VEGF family members (including VEGF-C) for broader disease control.
• Market Sizing: By 2030, an estimated 900,000 eyes in the US will be treated for wet AMD alone; total eyes (including DME) expected to reach 1.7 million.
• Logistical Burden: Real-world data shows >40% patient attrition in Year 1 due to barriers like distance, transportation, and competing health issues; 4150 aims to eliminate these barriers.
• Payer Landscape: 90% of patients are Medicare-covered; payers acknowledge limitations of current therapies and support a range of pricing for improved durability.
• Team: Management highlighted a 30-year industry veteran team with experience in launching multiple retinal therapeutics, including prior work with Port Delivery Systems.